Hassan Azzazy is a distinguished university professor of chemistry (2003-present) at The American University in Cairo (AUC). He was the chairman of the chemistry department and was the associate dean for graduate studies and research at the School of Sciences and Engineering, AUC. He is the founder of the Novel Diagnostics and Therapeutics research group and the director of the International Medical Laboratory Scientists training program at AUC.

Azzazy was a postdoctoral fellow and assistant professor at the University of Maryland School of Medicine, Baltimore, MD (1995-2002). Azzazy is a graduate of Alexandria University, Egypt and received his PhD from the School of Biomedical Sciences, University of North Texas Health Science Center, Fort Worth, TX (1994). He holds two board certifications in Clinical Chemistry and Molecular Diagnostics from the American Board of Clinical Chemistry, Washington, DC. He is certified as a Specialist in Chemistry by the Board of Certification, the American Society for Clinical Pathology in Chicago, IL.

Azzazy has over 28 years of experience in biomedical research, and he is the founder of the Novel Diagnostics and Therapeutics research group. A core interest of this group is the development of innovative diagnostics for accurate and affordable detection of biomarkers of infectious agents and cancer. Detection strategies combine the use of nanosensors, chips, smartphones, 3D printers, and/or robotics. He is also interested in drug design, subcellular targeting of drugs using smart biodegradable nanocarriers, and the development of biodegradable honey chitosan nanofibers for use as antibacterial wound dressings.

Azzazy authored over 85 scientific publications in international refereed journals, 70 conference presentations, and 25 book chapters. He serves on the editorial boards of Clinical Biochemistry (Elsevier), Clinica Chimica Acta (Elsevier), and Clinical Chemistry Laboratory Medicine (De Gruyter). Azzazy has co-founded two nanomedicine startup companies. He is the CTO of D-Kimia, LLC, innovative diagnostic solutions and the CEO of NanoEbers, LLC for nanofiber wound dressings.